Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Show more

Location: 4000 Shoreline Court, South San Francisco, CA, 94080, United States | Website: https://www.kezarlifesciences.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

32.95M

52 Wk Range

$3.62 - $9.20

Previous Close

$4.51

Open

$4.50

Volume

42,289

Day Range

$4.42 - $4.67

Enterprise Value

-66.79M

Cash

114.4M

Avg Qtr Burn

-17.14M

Insider Ownership

11.57%

Institutional Own.

59.28%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Zetomipzomib (KZR-616) Details Autoimmune Hepatitis	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KZR-261 Details Solid tumor/s, Melanoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zetomipzomib (KZR-616) Details Chronic inflammatory disorder, Chronic kidney disease, Inflammatory disease, Kidney disease, Lupus nephritis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KZR-616 Details Chronic inflammatory disorder, Inflammatory disease, Autoimmune disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.